Related Experiment Video

Updated: Oct 6, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.3K

Analysis of 5-Azacytidine Resistance Models Reveals a Set of Targetable Pathways

Lubomír Minařík1,2, Kristýna Pimková1, Juraj Kokavec1

  • 1BIOCEV, 1st Medical Faculty, Charles University, 25250 Vestec, Czech Republic.

Cells
|January 21, 2022
PubMed

Insights

Researchers developed a 5-azacytidine (AZA) resistant myelodysplastic syndrome (MDS) cell model to study resistance mechanisms. This model revealed molecular targets for improved hypomethylating agent (HMA) therapy in MDS and acute myeloid leukemia (AML).

Area of Science:

  • Hematology
  • Cancer Biology
  • Molecular Oncology

Background:

  • Myelodysplastic syndrome (MDS) cells develop resistance to hypomethylating agents (HMA), a key treatment, hindering therapeutic efficacy.
  • Understanding HMA resistance is crucial for preventing progression to acute myeloid leukemia (AML).

Purpose of the Study:

  • To develop and validate a novel cellular model for studying 5-azacytidine (AZA) resistance in MDS/AML.
  • To identify molecular pathways and mechanisms underlying AZA resistance in MDS/AML cells.

Main Methods:

  • Development of an AZA-resistant MDS/AML cell line model.
  • Validation of the model using in vivo transplantation into immunocompromised mice.
  • Analysis of mRNA expression and DNA variants to identify deregulated pathways.

Main Results:

  • The AZA-resistant model demonstrated stable resistance validated through transplantation.
  • Observed deregulation of cancer-related pathways, notably phosphatidylinositol-3-kinase (PI3K) signaling, in resistant cells.
  • Inhibitors targeting these pathways reduced proliferation but did not restore AZA sensitivity.

Conclusions:

  • Identified molecular mechanisms contributing to HMA resistance in MDS/AML.
  • These mechanisms represent potential therapeutic targets to overcome resistance and improve treatment outcomes.
  • Findings offer new strategies for managing AZA therapy progression in MDS and AML.
Keywords:
AzacytidineCDX micePI3K/AKT signalingmyelodysplastic syndromeresistance

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.3K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.4K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.2K
DNA Damage can Stall the Cell Cycle02:37

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.4K